Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.

Tettero, Jesse M; Ngai, Lok Lam; Bachas, Costa; Breems, Dimitri A; Fischer, Thomas; Gjertsen, Bjorn T; Gradowska, Patrycja; Griskevicius, Laimonas; Janssen, Jeroen J W M; Juliusson, Gunnar; Maertens, Johan; Manz, Markus G; Pabst, Thomas; Passweg, Jakob; Porkka, Kimmo; Valk, Peter J M; Löwenberg, Bob; Ossenkoppele, Gert J; Cloos, Jacqueline (2023). Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. Haematologica - the hematology journal, 108(10), pp. 2794-2798. Ferrata-Storti Foundation 10.3324/haematol.2022.282639

[img]
Preview
Text
11047-Article_Text-80846-1-10-20230406.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (2MB) | Preview

Not available.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Pabst, Thomas Niklaus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0390-6078

Publisher:

Ferrata-Storti Foundation

Language:

English

Submitter:

Pubmed Import

Date Deposited:

11 Apr 2023 14:02

Last Modified:

20 Jun 2024 08:56

Publisher DOI:

10.3324/haematol.2022.282639

PubMed ID:

37021540

BORIS DOI:

10.48350/181594

URI:

https://boris.unibe.ch/id/eprint/181594

Actions (login required)

Edit item Edit item
Provide Feedback